Senesco Technologies (ELOX)
(Delayed Data from OTC)
$0.00 USD
0.00 (0.00%)
Updated Sep 25, 2024 01:35 PM ET
NA Value
NA Growth NA Momentum NA VGMBrokerage Reports
0 items in cart
Senesco Technologies Inc. [ELOX]
Reports for Purchase
Showing records 1 - 20 ( 21 total )
Company: Senesco Technologies Inc.
Industry: Medical - Biomedical and Genetics
Company: Senesco Technologies Inc.
Industry: Medical - Biomedical and Genetics
Bearish Outlook on Upcoming ELX-02 Readout Expected 1H22; PT to $0.50
Provider: H.C. Wainwright & Co., Inc.
Analyst: FEIN A
Company: Senesco Technologies Inc.
Industry: Medical - Biomedical and Genetics
Poor Evidence Plagues ELX-02 Expansion to Alport Syndrome
Provider: H.C. Wainwright & Co., Inc.
Analyst: FEIN A
Company: Senesco Technologies Inc.
Industry: Medical - Biomedical and Genetics
Underwhelming ELX-02 Top Line - Our Thoughts; PT Down to $1
Provider: H.C. Wainwright & Co., Inc.
Analyst: FEIN A
Company: Senesco Technologies Inc.
Industry: Medical - Biomedical and Genetics
Negative Outlook For Approaching ELX-02 Readout; PT to $2
Provider: H.C. Wainwright & Co., Inc.
Analyst: FEIN A
Company: Senesco Technologies Inc.
Industry: Medical - Biomedical and Genetics
Company: Senesco Technologies Inc.
Industry: Medical - Biomedical and Genetics
ELX-02 Phase 2 In CF Remains on Track, Pipeline expands to Epidermolysis Bullosa; Reit Neutral and $3 PT
Provider: H.C. Wainwright & Co., Inc.
Analyst: FEIN A
Company: Senesco Technologies Inc.
Industry: Medical - Biomedical and Genetics
Platform Future Defined by Zikani Acquisition, Potential For ELX-02
Provider: H.C. Wainwright & Co., Inc.
Analyst: FEIN A
Company: Senesco Technologies Inc.
Industry: Medical - Biomedical and Genetics
Pipeline Strategy Rewritten Around Broader Ribosomal RNA Therapeutics-Can the Butterfly Emerge?
Provider: H.C. Wainwright & Co., Inc.
Analyst: FEIN A
Company: Senesco Technologies Inc.
Industry: Medical - Biomedical and Genetics
CF Program Data in 1H21, Pre-clinical Assets Continue to Take Shape; Reit Neutral and $3 PT
Provider: H.C. Wainwright & Co., Inc.
Analyst: FEIN A
Company: Senesco Technologies Inc.
Industry: Medical - Biomedical and Genetics
Minor Progress Updates as CF Program Readout Slated for 1H21, Reit Neutral and $3 PT
Provider: H.C. Wainwright & Co., Inc.
Analyst: FEIN A
Company: Senesco Technologies Inc.
Industry: Medical - Biomedical and Genetics
Continue to Await Data in CF; Reiterate Neutral and $3 PT
Provider: H.C. Wainwright & Co., Inc.
Analyst: FEIN A
Company: Senesco Technologies Inc.
Industry: Medical - Biomedical and Genetics
While Awaiting Data in CF a Look at Earlier Stage Assets; Reiterate Neutral and $3 PT
Provider: H.C. Wainwright & Co., Inc.
Analyst: FEIN A
Company: Senesco Technologies Inc.
Industry: Medical - Biomedical and Genetics
Awaiting ELX-02 Data in CF Patients Anticipated 1H20,
Provider: H.C. Wainwright & Co., Inc.
Analyst: FEIN A
Company: Senesco Technologies Inc.
Industry: Medical - Biomedical and Genetics
Despite CF Program Steps Forward, Phase 2 ELX-02 Data in CF Patients Remains on Horizon.
Provider: H.C. Wainwright & Co., Inc.
Analyst: FEIN A
Company: Senesco Technologies Inc.
Industry: Medical - Biomedical and Genetics
Spotlight on NACFC 2019: Hot Topics and Abstracts of Interest
Provider: H.C. Wainwright & Co., Inc.
Analyst: FEIN A
Company: Senesco Technologies Inc.
Industry: Medical - Biomedical and Genetics
ELX-02 Development in CF and Cystinosis, Clinical Data on Horizon; Reit Neutral and $10 PT
Provider: H.C. Wainwright & Co., Inc.
Analyst: FEIN A
Company: Senesco Technologies Inc.
Industry: Medical - Biomedical and Genetics
Preclinical Development in Retinal Disorders; We Maintain Our ELX-02 Reservations; Reit Neutral and $10 PT
Provider: H.C. Wainwright & Co., Inc.
Analyst: FEIN A
Company: Senesco Technologies Inc.
Industry: Medical - Biomedical and Genetics
Update from the European Cystic Fibrosis Society Basic Science Conference
Provider: H.C. Wainwright & Co., Inc.
Analyst: FEIN A